The investigators intend to check whether the efficacy of a TBE-vaccine is substantially deteriorated in patients with rheumatoid arthritis who are treated with drugs which suppress the immune system. The investigators aim to detect a difference of at least 10 % compared to healthy individuals (historical controls) in protection when analysed with serology. If the investigators detect a difference, the investigators will continue to explore whether protection can be achieved by additional doses
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
68
Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
Dept infectious diseases
Helsingfors, Finland
Dept infectious diseases
Eskilstuna, Sweden
Dept. infectious diseases
Eskilstuna, Sweden
Department of infectious diseases
Örebro, Sweden
Department of infectious diseases
Stockholm, Sweden
Dept infectious diseases
Uppsala, Sweden
Seroconversion rate
The humoral response to TBE-vaccine
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.